Showing 681 - 700 results of 2,299 for search 'Patient Number 9', query time: 0.08s Refine Results
  1. 681
  2. 682

    Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... by Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman

    Published 2023-01-01
    “…This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). …”
    Get full text
    Article
  3. 683
  4. 684
  5. 685
  6. 686
  7. 687

    Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses... by Brian Rini, Mariangela Mariani, Alessandra di Pietro, Paul Nathan, Christian Kollmannsberger, Marc-Oliver Grimm, Martin H Voss, Bradley A McGregor, Mehmet A Bilen, Yoshihiko Tomita, Bo Huang, Robert Amezquita, Matthew Tucker, Yu-Wei Chen

    Published 2024-07-01
    “…Objective We report post hoc analyses of efficacy with first-line avelumab plus axitinib or sunitinib according to baseline neutrophil-to-eosinophil ratio (NER) in patients with advanced renal cell carcinoma (aRCC) from the JAVELIN Renal 101 phase 3 trial.Methods and analysis Progression-free survival (PFS), overall survival (OS) and objective response per baseline NER were analysed in the overall population and in patients with programmed death ligand 1 (PD-L1+) tumours. …”
    Get full text
    Article
  8. 688

    Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with... by Jianrong Zhang, Yu Huang, Hengrui Liang, Wenhua Liang, Jianxing He, Yiyin Zhang, Jiaxi He, Jieyu Wu, Long Jiang, Shiyan Tang, Qihua He, Lindsey Tristine Hamblin, Zhiheng Xu, Yaoqi Chen, Difei Chen, Xinyu Wang, Kexin Deng, Shuhan Jiang, Jiaqing Zhou, Jiaxuan Xu, Xuanzuo Chen

    Published 2018-09-01
    “…Pooling analysis presented no systematic bias when comparing treatment effects of both assessments (ORR: OR=1.02 (95% CI 0.97 to 1.07), p=0.42, I2=0%; DCR: OR=0.97 (95% CI 0.92 to 1.03), p=0.32, I2=0%); PFS: HR=1.01 (95% CI 0.99 to 1.02), p=0.32, I2=0%; TTP: HR=1.04 (95% CI 0.95 to 1.14), p=0.37, I2=0%), regardless of funding source, mask, region, tumour type, study design, number of enrolled patients, response assessment criteria, primary endpoint and trials with statistically consistent/inconsistent inferences. …”
    Get full text
    Article
  9. 689
  10. 690

    Polymerized-Type I Collagen Downregulates Inflammation and Improves Clinical Outcomes in Patients with Symptomatic Knee Osteoarthritis Following Arthroscopic Lavage: A Randomized,... by Janette Furuzawa-Carballeda, Guadalupe Lima, Luis Llorente, Carlos Nuñez-Álvarez, Blanca H. Ruiz-Ordaz, Santiago Echevarría-Zuno, Virgilio Hernández-Cuevas

    Published 2012-01-01
    “…To evaluate the effect of intraarticular injections of polymerized collagen after arthroscopic lavage on inflammation and clinical improvement in patients with knee osteoarthritis (OA). Methods. Patients (n=19) were treated with 6 intraarticular injections of 2 mL of polymerized collagen (n=10) or 2 mL of placebo (n=9) during 3 months. …”
    Get full text
    Article
  11. 691

    Nissen-Sleeve procedure versus laparoscopic Roux-en-Y gastric bypass in patients with morbid obesity and gastro-oesophageal reflux disease: protocol for a non-inferiority randomise... by Jan A Apers, Martin Dunkelgrun, Ivonne Leeuwenburgh, Judith W H 't Hart, Bo J Noordman, Laser U Biter

    Published 2022-06-01
    “…The aim of this study is to compare effectiveness of Nissen-Sleeve with LRYGB.Method and analysis This is a single-centre, phase III, parallel-group randomised controlled trial in a high-volume bariatric centre in the Netherlands. A total of 88 patients with morbid obesity and GORD will be randomised to evaluate non-inferiority of Nissen-Sleeve versus LRYGB (non-inferiority margin 15%, power 80%, one-sided α 0.025, 9% drop out). …”
    Get full text
    Article
  12. 692

    Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and i... by Sofia Ramiro, Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Lianne S Gensler, Helena Marzo-Ortega, Natasha de Peyrecave, Victoria Navarro-Compán, Tetsuya Tomita, Carmen Fleurinck, Ute Massow, Thomas Vaux

    Published 2025-01-01
    “…Active inflammatory bowel disease and anterior uveitis EAIRs were 0.8 and 0.7, respectively. 202/303 (66.7%) patients completed Week 256. 42 (13.9%) patients discontinued treatment due to TEAEs.Efficacy at Week 48 was maintained for 5 years. …”
    Get full text
    Article
  13. 693

    Impact of multimorbidity on long-term outcomes in older adults with non-ST elevation acute coronary syndrome in the North East of England: a multi-centre cohort study of patients u... by Chris Wilkinson, Vijay Kunadian, Benjamin Beska, Abdulla A Damluji, Hanna Ratcovich, Greg B Mills

    Published 2022-07-01
    “…The primary composite outcome was all-cause mortality, myocardial infarction, stroke, urgent repeat revascularisation or significant bleeding.Results Mean age was 80.9 (±6.1) years. The cohort median CCI score was 5 (IQR 4–7). …”
    Get full text
    Article
  14. 694

    Influence of the metabolic control in patients with type 1 diabetes on their oral health status and the need for orthodontic treatment in a group of Spanish children (aged 6–12 yea... by Adrián Curto, Cristina Gómez-Polo, Daniel Curto, Marta Muñoz-Bruguier, Mari Cruz Lorenzo-Luengo, Javier Montero

    Published 2025-01-01
    “…In the group of patients with poor metabolic control, a significant increase was observed in the number of decayed teeth (1.83 ± 1.36), filled teeth (1.05 ± 0.84), and DMF-T score (3.14 ± 1.87) compared to patients with good metabolic control (1.38 ± 1.20 decayed teeth; 0.88 ± 0.86 filled teeth; DMF-T score 2.46 ± 1.87). …”
    Get full text
    Article
  15. 695
  16. 696
  17. 697
  18. 698
  19. 699
  20. 700